TO: OLIVIER HENRY, PRESIDENT OF BIO-THERAPY REPORT LLC
FROM: THE OFFICE OF THE PRESIDENT OF VERDUS PHARMACEUTICALS
SUBJECT: THE HART STUDY
DATE: NOVEMBER 1, 2007
CC: ALL EMPLOYEES OF VERDUS PHARMACEUTICALS
Dear Mr. Henry,
This Memo shall confirm receipt of your Letter dated October 26th, 2007 in which you informed the Board of
Directors of Verdus Pharmaceuticals that you will be suspending funding of the Hart Study and the Lullabye
Project. While the early promise of Dr. Calvin Hart’s research was cause for our shared optimism and
jubilation, the Board cannot deny the fact that all twenty of Dr. Hart’s Patients in Group A failed to reach
maturation and were therefore unable to be harvested.
The Board admits that the study was a failure, and that the long term viability of Dr. Hart’s genetic
modifications remain very much in doubt. However, all scientific theories must be put to the test, and the
Board roundly rejects your claim that “faulty” medical research or our “inexperienced personnel” are
somehow to blame. Verdus Pharmaceuticals is a proud family company with a rich tradition of pioneering
medicine, and the Board stands behind all of our employees, many of whom will now have to be laid off.
Finally, and most important, the Board asks you to consider the following:
Even in failure, we must celebrate the date, always grateful for science’s Impossible Puzzles and elegant
solutions, and knowing full well that our confederates will carry on this Historic Fight.
So, let them always remember the first shot, the first name of war, and know well that it was yours.
Office of the President